Levilimab · Ilsira
Monoclonal antibody
Also known as BCD-089
Evidence outlook
Approved: Rheumatoid arthritis (Ilsira, levilimab) (RU)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also approved (2)
- Rheumatoid arthritis (Ilsira, levilimab)
- Cytokine release syndrome in severe COVID-19 (Ilsira, levilimab)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SOLAR NCT04227366 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled trial in 154 patients that measured ACR20 response, a validated rheumatoid arthritis disease-activity measure, at week 12. Levilimab combined with methotrexate produced a much higher response rate than placebo combined with methotrexate (68.6% vs 38.5%). Registry: NCT04227366 | 3 | ACR 20 response (Week 12); Low disease activity (Week 24) 2021-03-15 | ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). | Reliable signal | link ↗ |
View 1 more trial
NCT05800327 NCT05800327 · Rheumatoid Arthritis Registry: NCT05800327 | 3 | Safety primary endpoint (Stage 1) (Up to day 71); Low disease activity (Stage 2) (Up to Week 24) 2024-09 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other IL-6 receptor drugs
BAT1806, Sarilumab, tocilizumab. Compare all 4 IL-6 receptor drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for COVID-19: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Levilimab (Ilsira): this drug | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.